首页>投融资
Inflammatix
E~PreIPO
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system using algorithms to generate clinically actionable results.In October 2020, Inflammatix announced a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority.In October 2020, Inflammatix announced a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority
基本信息
-
公司全称Inflammatix Inc
-
类型分子诊断技术及产品研发商
-
产业领域试剂/耗材、检测服务
-
公司人数15~50人
-
地址863 Mitten Road,Suite 104,Burlingame; US;
-
联系电话
-
邮箱info@inflammatix.com
-
成立时间2016-01-01
投融资
-
2024-09-12E~PreIPO5700万美元Khosla VenturesThink.HealthNorthpond VenturesD1 Capital PartnersIberis CapitalVesalius BiocapitalOSF HealthCareRAW Ventures
-
2021-03-16D轮1.02亿美元Khosla VenturesD1 Capital PartnersThink.Health VenturesOSF HealthCareNorthpond Ventures
-
2020-09-29未透露110万美元DARPA
-
2020-01-10C轮3200万美元Northpond VenturesGray Sky Venture PartnersThink.Health VenturesKhosla Ventures
- 加载更多
相关投融资企业
E~PreIPO
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system using algorithms to generate clinically actionable results.In October 2020, Inflammatix announced a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority.In October 2020, Inflammatix announced a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority
种子轮
HeMemics Biotechnologies是一家生物技术公司，致力于开发快速诊断测试平台，HEMEMICS技术使医院能够在几秒钟内（而不是几天内）快速识别传染病病原体，而费用却很少。
B轮
科医联创（浙江）生物科技集团有限公司成立于2010年，原名上海科医联创生物科技有限公司，是一家专注于肿瘤分子诊断技术和细胞技术研发与商业化应用的国家级高新技术企业。目前，集团全资控股四家检验实验室及一家细胞技术公司，已经完成了上海研发总部、多个区域性第三方医学检验所、GMP生产车间等多地域战略布局。基于战略定位，公司已经在精准医学领域的分子检测板块和体外药敏检测板块以及细胞技术领域进行了重点开发，并且与国内多家知名三甲医院开展新技术临床研究。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息